Table 4. Attributable risk estimates with 95% CIs for an admission for myocarditis; exposures with elevated RIs with p < 0.001 0–6 days post-vaccine and 0 to 27 days post a laboratory confirmed SARS-CoV-2 in the SCCS analysis using the dataset that includes infections in unvaccinated individuals.

Vaccine exposure	Admissions in risk period	RI	Attributable fraction	Attributable cases	Doses	Attributable risk per million vaccinations (95% CI)
0 to 6 days before admission 16 to 39 year olds
Dose 1 ChAdOx1	9	5.23	0.809	7.3	2,099,584	3.5 (2.6,3.9)
Dose 1 BNT162b2	18	2.23	0.552	9.9	9,705,976	1.02 (0.5,1.3)
Dose 2 BNT162b2	40	5.34	0.813	32.5	9,519,878	3.4 (3.1,3.6)
Booster BNT 162b2	17	4.38	0.772	13.1	5,319,875	2.5 (2.0,2.8)
Dose 1 mRNA 1273	8	8.69	0.885	7.1	1,023,825	6.9 (5.9,7.4)
Dose 2 mRNA 1273	38	56.48	0.982	37.3	881,058	42.4 (41.9,42.7)
Booster mRNA 1273	11	7.88	0.873	9.6	2,144,219	4.5 (3.9,4.8)
Vaccine exposure	Admissions in risk period	RI	Attributable fraction	Attributable cases	Doses	Attributable risk per million vaccinations (95% CI)
0 to 6 days before admission all 16+ year olds
Dose 2 BNT162b2: males	40	4.42	0.774	31.0	8,734,711	3.5 (3.1,3.8)
Dose 1 mRNA 1273: males	9	10.48	0.905	8.1	747,072	10.9 (9.6,11.5)
Dose 2 mRNA 1273: males	35	58.24	0.983	34.4	625,871	55.0 (54.3,55.3)
Booster mRNA 1273: males	12	3.8	0.737	8.8	3,539,697	2.5 (1.7,2.9)
Dose 2 mRNA 1273: females	4	23.26	0.957	3.8	498,121	7.7 (6.8,7.9)
SARS-CoV-2 infection 0–27 days before admission	Admissions in risk period	RI	Attributable fraction	Attributable cases	Cases	Attributable risk per million infections
16 to 39 year olds day 0	15	6.98	0.857	12.9	8,398,257	1.5 (1.4–1.6)
≥40 year olds day 0	37	23.56	0.958	35.4	6,570,699	5.4 (5.6, 5.5)
16–39 year olds days 1–27	113	2.09	0.522	58.9	8,398,257	7.0 (5.5, 8.3)
≥40 year olds days 1–27	124	3.07	0.674	83.6	6,570,699	12.7 (11.3, 13.9)

CI, confidence interval; RI, relative incidence; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; SCCS, self-controlled case series.